Home › PBT2 Recommended For Orphan Designation In Europe
 

Keywords :   


PBT2 Recommended For Orphan Designation In Europe

2015-04-29 03:49:41| drugdiscoveryonline Home Page

Prana Biotechnology is pleased to announce the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the European Commission (EC)

Tags: europe recommended designation orphan

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.11Sports service SPOTV adopts Zixi for affiliate delivery
26.11EQT to sell Melita to Goldman Sachs Alternatives
26.11U.S. spending on standalone pay TV increased in Q3 2024
26.11yuma 1~60
26.11 GARMIN Approach S20
26.1135130
26.11HOTEL4 DVD-BOX
26.11 VHS
More »